BlackRock
APRE icon

BlackRock’s Aprea Therapeutics APRE Stock Holding History

BlackRock’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.75K Sell
7,173
-1,331
-16% -$1.11K ﹤0.01% 5486
2026
Q1 		$6.49K Hold
8,504
– – ﹤0.01% 5440
2025
Q4 		$7.25K Hold
8,504
– – ﹤0.01% 5312
2025
Q3 		$12.5K Hold
8,504
– – ﹤0.01% 5199
2025
Q2 		$14.4K Hold
8,504
– – ﹤0.01% 5182
2025
Q1 		$17.3K Hold
8,504
– – ﹤0.01% 5112
2024
Q4 		$28K Hold
8,504
– – ﹤0.01% 5053
2024
Q3 		$23.4K Hold
8,504
– – ﹤0.01% 4919
2024
Q2 		$34.6K Hold
8,504
– – ﹤0.01% 4927
2024
Q1 		$56.9K Hold
8,504
– – ﹤0.01% 4842
2023
Q4 		$40K Sell
8,504
-726
-8% -$2.97K ﹤0.01% 4992
2023
Q3 		$38.5K Sell
9,230
-13
-0.1% -$47 ﹤0.01% 5048
2023
Q2 		$29.1K Hold
9,243
– – ﹤0.01% 5156
2023
Q1 		$41K Sell
9,243
-26
-0.3% -$192 ﹤0.01% 5154
2022
Q4 		$61.4K Sell
9,269
-18
-0.2% -$190 ﹤0.01% 5173
2022
Q3 		$121K Sell
9,287
-52
-0.6% -$923 ﹤0.01% 5115
2022
Q2 		$140K Sell
9,339
-2,169
-19% -$50K ﹤0.01% 5132
2022
Q1 		$428K Sell
11,508
-103
-0.9% -$4.22K ﹤0.01% 4912
2021
Q4 		$667K Sell
11,611
-6,103
-34% -$539K ﹤0.01% 4790
2021
Q3 		$1.81M Sell
17,714
-167
-0.9% -$15.2K ﹤0.01% 4359
2021
Q2 		$1.74M Sell
17,881
-22,662
-56% -$2.09M ﹤0.01% 4337
2021
Q1 		$4.13M Sell
40,543
-885
-2% -$103K ﹤0.01% 4026
2020
Q4 		$4.08M Buy
41,428
+17,004
+70% +$8.09M ﹤0.01% 3784
2020
Q3 		$11.8M Buy
24,424
+449
+2% +$251K ﹤0.01% 3133
2020
Q2 		$18.6M Buy
23,975
+6,196
+35% +$4.07M ﹤0.01% 2834
2020
Q1 		$12.4M Buy
17,779
+581
+3% +$426K ﹤0.01% 2882
2019
Q4 		$15.8M Buy
+17,198
New +$9.47M ﹤0.01% 3015

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock's APRE Position: Q2 2026 in Review

BlackRock reduced its Aprea Therapeutics (APRE) stake by 16% in Q2 2026, selling an estimated $1.11K and leaving 7,173 shares worth $5.75K. The position accounts for ﹤0.01% of the portfolio, ranked #5486.

BlackRock first reported a position in APRE in Q4 2019 and has held it in 27 quarters since. The position peaked at $18.6M in Q2 2020. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

  • BlackRock held 7,173 shares of Aprea Therapeutics worth $5.75K as of Q2 2026.
  • BlackRock sold 1,331 Aprea Therapeutics shares in Q2 2026, an estimated $1.11K.
  • Aprea Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5486 holding.
  • BlackRock first reported a position in Aprea Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • BlackRock's Aprea Therapeutics position peaked at $18.6M in Q2 2020.
  • 28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.